Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report

Terceiro, Benivaldo Ramos Ferreira; Torraca, Tania Salgado de Souza; Braga, Frederico Pereira Bom; Martins, Ana Cristina da Costa; Brahim, Lúcia Regina; Saheki, Maurício Naoto; Miranda, Luciana de Freitas Campos; Schubach, Armando de Oliveira; Valete‐Rosalino, Cláudia Maria

doi:10.1590/0037-8682-0236-2018

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Brazil, the experience with pentamidine isethionate is almost limited to the Amazon region where the main ATL-causing species is L. (V.) guyanensis, which usually responds poorly to MA treatment (Brasil MS -Ministério da Saúde et al, 2017). In a reference center in Rio de Janeiro, pentamidine isethionate is a third-choice drug, used only in cases of contraindication, intolerance or poor response to MA treatment and amphotericin B (deoxycholate or liposomal) (Pimentel et al, 2011;Terceiro et al, 2019). Between 2001 and 2013, pentamidine isethionate was used in only 12 (1.2%) of the 997 treatments performed at that center (Brahim et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit

et al. 2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit

et al. 2019

View full text Add to dashboard Cite

“…In Brazil, meglumine antimoniate is used as the first choice for treating ATL (Ferreira et al, 2019). The dosage recommended by the Ministry of Health (MHB, 2017) for treating the cutaneous form is 20 mg/kg, for 20 days with intramuscular or intravenous administration.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of intralesional treatment in american tegumentary leishmaniasis in the amazon region: results and perspectives

Farias,

Santos,

Oliveira

et al. 2024

Cuad. Ed. Desar.

View full text Add to dashboard Cite

American Tegumentary Leishmaniasis (ATL) is an infectious disease transmitted to humans by the bite of infected phlebotomine sand flies, commonly known as "sand flies." In Brazil, ATL is a significant public health challenge, with a higher prevalence in the northern region, a predominance of males aged 20 to 40 years, and a higher incidence among the mixed-race population. Methodology: The study was conducted under the Education through Work for Health Program (PET-Saúde) in Santarém, Pará, between August and December 2022. Results: The predominant profile of ATL patients was adult male rural workers with cutaneous lesions mainly on the lower limbs. The most common clinical form was localized cutaneous lesion, representing over 90% of cases. Intralesional treatment with meglumine antimoniate was well-tolerated by patients, with few local side effects and a successful therapeutic response in most cases. Discussion: The results corroborated with the literature, showing the endemic profile of ATL in the Amazon region. Intralesional treatment proved to be effective and well-tolerated, being a relevant option for areas with limited resources and difficulties in accessing healthcare. Conclusion: The study provides evidence that intralesional treatment with meglumine antimoniate is an effective therapeutic option. Its high adherence suggests its consideration in public health policies for disease treatment. It is recommended that future studies expand the sample size and follow-up period to obtain more comprehensive information about this therapeutic approach.

show abstract

Drug Discovery and Development for Kinetoplastid Diseases

Caffrey

Steverding

Ferreira

et al. 2021

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

In this article, we review the disease, biology, and biochemistry of kinetoplastids, as well as the new drugs and drug candidates that have entered the clinic in the last decade. We also describe examples of the preclinical exploration of small molecules against various protein targets (e.g. cysteine proteases, the proteasome, and tubulin), as well as cutting‐edge molecular and computational strategies and technologies being brought to bear to discover and develop new antitrypanosomal drugs. For comprehensive descriptions of the disease, biology, and drug therapies prior to 2011, the reader is encouraged to review the article by P.M. Woster that appeared in 2010 in the seventh edition of Burger's Medicinal Chemistry, Drug Discovery, and Development, entitled Antiprotozoal/Antiparasitic Agents.

show abstract

Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report

Cited by 5 publications

References 11 publications

Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit

Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit

Evaluation of intralesional treatment in american tegumentary leishmaniasis in the amazon region: results and perspectives

Drug Discovery and Development for Kinetoplastid Diseases

Contact Info

Product

Resources

About